Phaseline

Companies › Meridigen Biotech

Meridigen Biotech: clinical trials, targets and expected readouts

1 active drug program in 1 registered trial: 1 Phase 1; Other; next expected readout Jul 2027.

Open in Phaseline: competitors, likelihood bands and readouts Company report

Programs

DrugTargetHighest phaseConditionsNext expected readout
UMC119-01
Human umbilical cord-derived mesenchymal stem cells
–Phase 1Bronchopulmonary DysplasiaJul 2027

Trials

Registry idDrugPhaseConditionsAreaExpected readout
NCT03631420UMC119-01Phase 1Bronchopulmonary DysplasiaOtherJul 2027

Targets

No annotated target.

Companies with the same targets

–

Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.